Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Archives of Psychiatry and Clinical Neuroscience

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00406-015-0634-9PMID 26303414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systematic reviews and meta-analysis.

  2015cited by this paper
• A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

  2015influential reference
• ["Mid-stimulation psychosis" in the course of in vitro fertilization procedure with the use of clomiphene citrate and bromocriptine - case study].

  2014cited by this paper
• A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia.

  2014influential reference
• Scale for the Assessment of Negative Symptoms

  2014cited by this paper
• Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia

  2014influential reference
• [Oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia].

  2014cited by this paper
• The use of electroconvulsive therapy and general anaesthesia in catatonic schizophrenia complicated by clozapine - induced pancytopenia - case report.

  2014cited by this paper
• A meta-analysis and theoretical critique of oxytocin and psychosis: prospects for attachment and compassion in promoting recovery.

  2014cited by this paper
• Do atypical antipsychotics improve cognition?

  2014cited by this paper
• Improving social perception in schizophrenia: the role of oxytocin.

  2013cited by this paper
• Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

  2013influential reference
• Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls

  2013cited by this paper
• Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia

  2012cited by this paper
• Intranasal Treatment of Central Nervous System Dysfunction in Humans

  2012cited by this paper
• Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

  2012cited by this paper
• Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors.

  2012cited by this paper
• Emotion recognition and oxytocin in patients with schizophrenia

  2011cited by this paper
• Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia

  2011cited by this paper
• Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine

  2011cited by this paper
• Social effects of oxytocin in humans: context and person matter.

  2011cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.

  2011influential reference
• Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

  2010influential reference
• Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS).

  2010cited by this paper
• The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.

  2009cited by this paper
• What we know: findings that every theory of schizophrenia should explain.

  2009cited by this paper
• Oxytocin and social perception: oxytocin increases perceived facial trustworthiness and attractiveness.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long‐term adverse consequences of drug use?

  2008cited by this paper
• Oxytocin increases trust in humans

  2005cited by this paper
• Systematic reviews and meta-analysis.

  2005cited by this paper
• Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment

  2004cited by this paper
• The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations

  1989cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• A multiverse meta-analysis of oxytocin administration studies.

  2025cites this paper
• An exploration of blood-based biomarkers of negative symptoms of psychosis in men.

  2024cites this paper
• Is the "social hormone" oxytocin relevant to psychotherapy treatment outcomes? A systematic review of observational and experimental studies.

  2024cites this paper
• Intranasal Oxytocin Combined With Social Skills Training for Schizophrenia: An Add-on Randomized Controlled Trial

  2024cites this paper
• Large household reduces dementia mortality: A cross-sectional data analysis of 183 populations

  2022cites this paper
• Multiple Aspects of Inappropriate Action of Renin–Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases

  2022cites this paper
• Large household reduces dementia mortality.

  2022cites this paper
• Neuroimaging oxytocin modulation of social reward learning in schizophrenia

  2022cites this paper
• Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia.

  2022cites this paper
• MDMA for the Treatment of Negative Symptoms in Schizophrenia

  2022cites this paper
• Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology

  2021cites this paper
• Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Effect of oxytocin nasal spray on auditory automatic discrimination measured by mismatch negativity

  2021cites this paper
• Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)

  2021cites this paper
• Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia

  2021cites this paper
• A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation

  2020cites this paper
• Sublingual Oxytocin With Clozapine in a Patient With Persisting Psychotic Symptoms, Suicidal Thinking With Self-Harm.

  2020cites this paper
• Negative symptoms at the prodromal stage of schizophrenia at a young age (current problems of diagnostics and treatment)

  2020cites this paper
• Schizophrenia

  2020cites this paper
• Clinical convergence of autism, schizophrenia, and Alzheimer’s disease: The case of social cognition

  2020cites this paper
• Негативные симптомы на инициальном этапе шизофрении в юношеском возрасте (современные аспекты дифференциально-диагностической оценки и терапии)

  2020cites this paper
• Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial.

  2019cites this paper
• Effects of oxytocin on empathy, introspective accuracy, and social symptoms in schizophrenia: A 12-week twice-daily randomized controlled trial.

  2019cites this paper
• Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.

  2019cites this paper
• The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

  2019cites this paper
• Role of oxytocin in social cognition in psychosis spectrum disorders

  2019cites this paper
• Évolution de la symptomatologie négative chez les patients schizophrènes hospitalisés

  2019cites this paper
• Overview of Human Oxytocin Research.

  2018cites this paper
• Oxytocin and Schizophrenia Spectrum Disorders.

  2018cites this paper
• Social Motivation in Schizophrenia: The Impact of Oxytocin on Vigor in the Context of Social and Nonsocial Reinforcement

  2018cites this paper
• Sex and Pharmacological Sexual Enhancement

  2017cites this paper
• Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis.

  2017cites this paper
• Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence

  2017cites this paper
• Oxytocin and the Social Brain.

  2017cites this paper
• The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study.

  2017cites this paper
• Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

  2017cites this paper
• Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia

  2017cites this paper
• Pharmacological interventions in clozapine-refractory schizophrenia

  2017influential citation
• Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review

  2017cites this paper
• Oxytocin improves facial emotion recognition in young adults with antisocial personality disorder.

  2017cites this paper
• Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward

  2017influential citation
• Intranasal delivery of antipsychotic drugs.

  2017cites this paper
• A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

  2017cites this paper
• Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.

  2017cites this paper
• Coding errors lead to unsupported conclusions: a critique of Hofmann et al. (2015)

  2016cites this paper
• Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study.

  2016cites this paper
• Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries

  2016cites this paper
• Title: Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis Author:

  2016influential citation
• Regelbehandlung mit Antipsychotika ist nicht ausreichend effektiv

  2016cites this paper
• Treating Negative Symptoms in Schizophrenia: an Update

  2016cites this paper
• Do we need oxytocin to treat schizophrenia? A randomized clinical trial.

  2016cites this paper